Source:http://linkedlifedata.com/resource/pubmed/id/17201465
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001613,
umls-concept:C0007776,
umls-concept:C0022655,
umls-concept:C0066908,
umls-concept:C0086418,
umls-concept:C0205369,
umls-concept:C0547047,
umls-concept:C0678951,
umls-concept:C0871261,
umls-concept:C1335671,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1879547,
umls-concept:C1948023,
umls-concept:C2911692
|
pubmed:issue |
6
|
pubmed:dateCreated |
2007-1-4
|
pubmed:abstractText |
The authors sought to investigate the role of a common single nucleotide polymorphism in the mu-opioid receptor gene (OPRM1) 118A > G for nociceptive sensory processing using event-related potentials (ERPs). Specific nociceptive (carbon dioxide [CO-sub-2]: 40% volume-to-volume [vol/vol] and 60% vol/vol) and nonnociceptive (hydrogen sulfide, 2 parts per million [ppm] and 4 ppm) stimuli were applied to the nasal mucosa of 45 volunteers. ERPs were recorded from a central lead. In this random sample, we found 37 noncarriers, 7 heterozygous carriers, and 1 homozygous carrier of the variant OPRM1 118G allele (allelic frequency, 10%). Amplitudes of nociceptive ERP in carriers of this allele were, on average, half as high as those of noncarriers. In discriminant analysis, ERP amplitude N1 response to the weaker nociceptive stimuli was the only ERP parameter that discriminated statistically significantly between carriers and noncarriers of the variant 118G allele. On the basis of N1-CO-sub-2 (40% vol/vol), the authors correctly backclassified 68.6% of the cases as carriers or noncarriers of the allele. The OPRM1 118A > G polymorphism specifically modulates nociceptive but not nonnociceptive cortical activation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0735-7044
|
pubmed:author | |
pubmed:copyrightInfo |
2006 APA, all rights reserved
|
pubmed:issnType |
Print
|
pubmed:volume |
120
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1218-24
|
pubmed:meshHeading |
pubmed-meshheading:17201465-Adult,
pubmed-meshheading:17201465-Aged,
pubmed-meshheading:17201465-Alleles,
pubmed-meshheading:17201465-Carbon Dioxide,
pubmed-meshheading:17201465-Cerebral Cortex,
pubmed-meshheading:17201465-DNA Mutational Analysis,
pubmed-meshheading:17201465-Dose-Response Relationship, Drug,
pubmed-meshheading:17201465-Evoked Potentials,
pubmed-meshheading:17201465-Female,
pubmed-meshheading:17201465-Gene Frequency,
pubmed-meshheading:17201465-Humans,
pubmed-meshheading:17201465-Male,
pubmed-meshheading:17201465-Middle Aged,
pubmed-meshheading:17201465-Pain,
pubmed-meshheading:17201465-Polymorphism, Genetic,
pubmed-meshheading:17201465-Reaction Time,
pubmed-meshheading:17201465-Receptors, Opioid, mu
|
pubmed:year |
2006
|
pubmed:articleTitle |
The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation.
|
pubmed:affiliation |
pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
|
pubmed:publicationType |
Journal Article
|